Wiskott-Aldrich Syndrome

Immune Disorder HSCT Protocol

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome

Baby Detect : Genomic Newborn Screening

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

Participation in a Research Registry for Immune Disorders

Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome

Gene Therapy for Wiskott-Aldrich Syndrome (WAS)

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990

Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)

A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients

Gene Therapy for WAS